Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Table 4 Relationship between physical activity, endurance time, and exertional dyspnea

		Observations^a	Correlation	P-value
Change from baseline in daily step count^b	Change from baseline in endurance time (s)	168	0.061	0.433
Change from baseline in daily step count^b	Change from baseline in duration of at least moderate activity (min)^b	168	0.640	<0.0001
Change from baseline in duration of at least moderate activity (min/day)^b	Change from baseline in endurance time (s)	168	-0.015	0.845
Change from baseline in endurance time (s)	Change from baseline in exertional dyspnea at isotime	216	-0.535	<0.0001

Pearson correlation for change from baseline in mean daily step count, mean duration of at least moderate activity (>3 metabolic equivalents), endurance time during constant work rate cycle ergometry to symptom limitation at 75% of the maximum work rate, and exertional dyspnea at isotime across the study (aclidinium and placebo treatment periods; ITT population).
^aNumber of observations used to calculate the correlation.
^bPatients who had ≥5 days with ≥22 h of valid data.
ITT, intent-to-treat.

ISSN: 1471-2466